Search: WFRF:(Launay F) >
Vaccine effectivene...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation : I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
-
- Rose, Angela M.C. (author)
- Epiconcept, Paris
-
- Nicolay, Nathalie (author)
- European Centre for Disease Prevention and Control
-
- Martín, Virginia Sandonis (author)
- Spanish National Centre for Microbiology
-
show more...
-
- Mazagatos, Clara (author)
- Carlos III Health Institute,CIBER Epidemiology and Public Health (CIBERESP)
-
- Petrović, Goranka (author)
- Croatian National Institute of Public Health, Zagreb
-
- Baruch, Joaquin (author)
- Health Promotion and Disease Prevention Directorate
-
- Denayer, Sarah (author)
- Sciensano
-
- Seyler, Lucie (author)
- Universitair Ziekenhuis Brussel
-
- Domegan, Lisa (author)
- Health Protection Surveillance Centre
-
- Launay, Odile (author)
- Cochin Hospital,National Institute for Health and Medical Research, France,Université Paris Cité
-
- Machado, Ausenda (author)
- National Institute of Health Dr. Ricardo Jorge
-
- Burgui, Cristina (author)
- CIBER Epidemiology and Public Health (CIBERESP),Health Research Institute of Navarra (IDISNA)
-
- Vaikutyte, Roberta (author)
- Lithuanian University of Health Sciences
-
- Niessen, F. Annabel (author)
- National Institute for Public Health and the Environment (RIVM)
-
- Loghin, Isabela I. (author)
- Grigore T. Popa University of Medicine and Pharmacy,St. Parascheva Clinical Hospital of Infectious Diseases
-
- Husa, Petr (author)
- University Hospital Brno,Masaryk University
-
- Aouali, Nassera (author)
- Luxembourg Institute of Health
-
- Panagiotakopoulos, George (author)
- National Public Health Organisation (EODY)
-
- Tolksdorf, Kristin (author)
- Robert Koch Institut
-
- Horváth, Judit Krisztina (author)
- Semmelweis University
-
- Howard, Jennifer (author)
- Epiconcept, Paris
-
- Pozo, Francisco (author)
- Spanish National Centre for Microbiology
-
- Gallardo, Virtudes (author)
- Dirección General de Salud Pública y Ordenación Farmacéutica
-
- Nonković, Diana (author)
- Teaching Public Health Institute of Split-Dalmatia County
-
- Džiugytė, Aušra (author)
- Health Promotion and Disease Prevention Directorate
-
- Bossuyt, Nathalie (author)
- Sciensano
-
- Demuyser, Thomas (author)
- Universitair Ziekenhuis Brussel
-
- Duffy, Róisín (author)
- Health Protection Surveillance Centre
-
- Nguyen, Liem Binh Luong (author)
- Cochin Hospital
-
- Kislaya, Irina (author)
- National Institute of Health Dr. Ricardo Jorge
-
- Martínez-Baz, Iván (author)
- Health Research Institute of Navarra (IDISNA),CIBER Epidemiology and Public Health (CIBERESP)
-
- Gefenaite, Giedre (author)
- Lund University,Lunds universitet,Aktivt och hälsosamt åldrande,Forskargrupper vid Lunds universitet,LU profilområde: Proaktivt åldrande,Lunds universitets profilområden,Active and Healthy Ageing Research Group,Lund University Research Groups,LU Profile Area: Proactive Ageing,Lund University Profile areas,Lithuanian University of Health Sciences
-
- Knol, Mirjam J. (author)
- National Institute for Public Health and the Environment (RIVM)
-
- Popescu, Corneliu (author)
- Victor Babes National Institute,Carol Davila University of Medicine and Pharmacy
-
- Součková, Lenka (author)
- University Hospital Brno
-
- Simon, Marc (author)
- Centre Hospitalier de Luxembourg
-
- Michelaki, Stella (author)
- National Public Health Organisation (EODY)
-
- Reiche, Janine (author)
- Robert Koch Institut
-
- Ferenczi, Annamária (author)
- Semmelweis University
-
- Delgado-Sanz, Concepción (author)
- CIBER Epidemiology and Public Health (CIBERESP),Carlos III Health Institute
-
- Makarić, Zvjezdana Lovrić (author)
- Croatian National Institute of Public Health, Zagreb
-
- Cauchi, John Paul (author)
- Health Promotion and Disease Prevention Directorate
-
- Barbezange, Cyril (author)
- Sciensano
-
- Van Nedervelde, Els (author)
- Universitair Ziekenhuis Brussel
-
- O’Donnell, Joan (author)
- Health Protection Surveillance Centre
-
- Durier, Christine (author)
- National Institute for Health and Medical Research, France
-
- Guiomar, Raquel (author)
- National Institute of Health Dr. Ricardo Jorge
-
- Castilla, Jesús (author)
- Health Research Institute of Navarra (IDISNA),CIBER Epidemiology and Public Health (CIBERESP)
-
- Jonikaite, Indrė (author)
- Lithuanian University of Health Sciences
-
- Bruijning-Verhagen, Patricia C.J.L. (author)
- National Institute for Public Health and the Environment (RIVM),University Medical Center Utrecht
-
show less...
-
(creator_code:org_t)
-
-
show more...
-
-
show less...
- 2023
- 2023
- English.
-
In: Eurosurveillance. - 1025-496X. ; 28:47
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.2...
-
show less...
Abstract
Subject headings
Close
- Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset<120 days after first booster dose.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Rose, Angela M.C ...
-
Nicolay, Nathali ...
-
Martín, Virginia ...
-
Mazagatos, Clara
-
Petrović, Gorank ...
-
Baruch, Joaquin
-
show more...
-
Denayer, Sarah
-
Seyler, Lucie
-
Domegan, Lisa
-
Launay, Odile
-
Machado, Ausenda
-
Burgui, Cristina
-
Vaikutyte, Rober ...
-
Niessen, F. Anna ...
-
Loghin, Isabela ...
-
Husa, Petr
-
Aouali, Nassera
-
Panagiotakopoulo ...
-
Tolksdorf, Krist ...
-
Horváth, Judit K ...
-
Howard, Jennifer
-
Pozo, Francisco
-
Gallardo, Virtud ...
-
Nonković, Diana
-
Džiugytė, Aušra
-
Bossuyt, Nathali ...
-
Demuyser, Thomas
-
Duffy, Róisín
-
Nguyen, Liem Bin ...
-
Kislaya, Irina
-
Martínez-Baz, Iv ...
-
Gefenaite, Giedr ...
-
Knol, Mirjam J.
-
Popescu, Corneli ...
-
Součková, Lenka
-
Simon, Marc
-
Michelaki, Stell ...
-
Reiche, Janine
-
Ferenczi, Annamá ...
-
Delgado-Sanz, Co ...
-
Makarić, Zvjezda ...
-
Cauchi, John Pau ...
-
Barbezange, Cyri ...
-
Van Nedervelde, ...
-
O’Donnell, Joan
-
Durier, Christin ...
-
Guiomar, Raquel
-
Castilla, Jesús
-
Jonikaite, Indrė
-
Bruijning-Verhag ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Infectious Medic ...
- Articles in the publication
-
Eurosurveillance
- By the university
-
Lund University